- Home
- DOMH vs ICCM Comparison
DOMH vs ICCM Comparison
Compare DOMH & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DOMH | ICCM |
|---|---|---|
| Founded | 1967 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 41.4M |
| IPO Year | 2010 | 2013 |
Fundamental Metrics
Financial Performance| Metric | DOMH | ICCM |
|---|---|---|
| Price | $3.64 | $0.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 85.7K | ★ 484.4K |
| Earning Date | 05-12-2026 | 05-27-2026 |
| Dividend Yield | ★ 23.45% | N/A |
| EPS Growth | ★ 34.03 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $123,104,000.00 | N/A |
| Revenue This Year | N/A | $139.51 |
| Revenue Next Year | N/A | $75.66 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 578.41 | N/A |
| 52 Week Low | $2.69 | $0.24 |
| 52 Week High | $8.40 | $1.40 |
Technical Indicators
Market Signals| Indicator | DOMH | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 68.30 | 28.57 |
| Support Level | $2.75 | N/A |
| Resistance Level | $5.09 | $0.33 |
| Average True Range (ATR) | 0.19 | 0.03 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 95.79 | 2.36 |
Price Performance
Historical ComparisonAbout DOMH Dominari Holdings Inc.
Dominari Holdings Inc through its various subsidiaries, is currently engaged in wealth management, investment banking, securities sales and trading and asset management. The company operates in two reportable business segments: Dominari Financial and Legacy AIkido. The Dominari Financial reportable business segment represents the Company's broker-dealer business, which is composed of mostly underwriting and transactional service activities. The Legacy AIkido reportable business segment includes Aikido Labs, which manages the investments holdings of the legacy entity. It generates the majority of its revenue from the Dominari Financial segment.
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.